Boehringer Ingelheim
Boehringer Ingelheim is a global pharmaceutical company based in Ingelheim am Rhein, Germany, with a focus on improving patient care through innovation. Established in 2010, the Boehringer Ingelheim Venture Fund specializes in early-stage investments in life sciences, biotechnology, and digital health. The fund targets groundbreaking therapeutics and novel technologies, emphasizing areas such as immuno-oncology, regenerative medicine, and disease-related biomarkers. It typically invests up to €15 million over the lifetime of a company, with a specific focus on North America and Europe/Israel. Boehringer Ingelheim's commitment to advancing biomedical research aims to enhance patient outcomes through pioneering science and the development of new therapeutic concepts.
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
Global Stem cell Technology is a veterinary biotech company to develop and produce state-of-the art stem cell products for horses and dogs.
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medical practitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
Aelin Therapeutics NV is a Belgian biotherapeutics company founded in 2017, focused on developing antibiotics and therapeutics utilizing its innovative Pept-in technology. This technology leverages protein aggregation to achieve functional knockdown of target proteins, making it applicable against challenging conditions such as Methicillin-resistant Staphylococcus aureus (MRSA) and other undruggable targets in humans. Aelin Therapeutics was established as a collaboration between VIB and partner universities including KU Leuven, VUB, and UGent, building on the pioneering research of noted structural biologists. The company has compiled a robust preclinical proof of concept data package, demonstrating the diverse applications of its technology across various biological targets, including bacteria, cancer cells, fungi, viruses, and plant cells. Aelin Therapeutics differentiates itself through the unique mechanism of action of its Pept-in technology, which allows for the rational design of biotherapeutics that can target intracellular spaces often inaccessible to conventional small molecules or antibodies. The company is headquartered in Heverlee, Belgium.
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.
Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.
Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.
Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.
Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.
Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.
Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):